UNSPSC 51162742: Telmesteine

This classification denotes a mucolytic agent with the molecular formula C7H11NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 124I3FE35T, chemically known as (-)-3-ethyl hydrogen (r)-3,4-thiazolidinedicarboxylate but more generally known as telmesteine, which bears US NIH Compound Identifier 65946. European Medicines Agency schedules Telmesteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10873MIG.

UNSPSC 51162742 Telmesteine is a Commodity code under which state and local governments procure pharmaceutical products and medical equipment for correctional facilities, public health departments, and other healthcare settings. Recent opportunities under this code show purchasing of parenteral nutrition and intravenous solutions for incarcerated populations, as well as emergency medical supplies such as naloxone and drug deactivation systems for community health programs. The work involves both product supply and specialized services—the Washington State Department of Corrections solicitation emphasizes documented experience preparing and delivering IV solutions, monitoring patient lab results, and adjusting nutrition preparations within tight service-level agreements (parenteral nutrition bags within 24 hours, other parenteral products within 8 hours). Issuing bodies span state correctional systems and county health departments; the Washington DOC solicitation encourages participation from small businesses, minority-owned businesses, women-owned businesses, and veteran-owned businesses under state set-aside and preference programs, with an aspirational 5% Small and Diverse Business Goal.

Recent activity appears concentrated in the Pacific Northwest and Southeast. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026, with quotes due October 7, 2026, seeking parenteral products and services for eight correctional facilities across three regions (West, Central, and East Washington), with DOC anticipating awards to up to three bidders per region under a contract term running November 26, 2026 through June 30, 2030 with firm pricing for two years. Separately, Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. Both opportunities require vendors to maintain specified insurance coverage, undergo background clearance, and comply with state licensure and drug-free workplace requirements.